Correction to: Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials

Luuk Wieske¹, Duncan Smyth^{2

3}, Michael P Lunn^{2

3}, Filip Eftimov¹, Charlotte E Teunissen⁴

Affiliations

¹ Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands.
² Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, UK.
³ UCL Queen Square Institute of Neurology, London, UK.
⁴ Neurochemistry Lab, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands. c.teunissen@amsterdamumc.nl.

Published Erratum

Luuk Wieske et al. Neurotherapeutics. 2021 Oct.

. 2021 Oct;18(4):2758.

doi: 10.1007/s13311-021-01157-9.

Luuk Wieske¹, Duncan Smyth^{2

3}, Michael P Lunn^{2

3}, Filip Eftimov¹, Charlotte E Teunissen⁴

¹ Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands.
² Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, UK.
³ UCL Queen Square Institute of Neurology, London, UK.
⁴ Neurochemistry Lab, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands. c.teunissen@amsterdamumc.nl.

No abstract available

Erratum for

Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials.
Wieske L, Smyth D, Lunn MP, Eftimov F, Teunissen CE. Wieske L, et al. Neurotherapeutics. 2021 Oct;18(4):2351-2367. doi: 10.1007/s13311-021-01136-0. Epub 2021 Oct 18. Neurotherapeutics. 2021. PMID: 34661878 Free PMC article. Review.